Similarly, a meta-analysis by Liu et al. of 5 randomized controlled trials suggested that there was no statistically significant difference in the risk of SCD between diabetes patients treated with GLP-1 receptor agonists and the placebo group (59). Here, GLP1R is linked to diabetes mellitus.